New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
08:22 EDTNVAXNovavax's experimental vaccine against new virus shows positive results
Novavax and The University of Maryland School of Medicine announced that an investigational vaccine candidate developed by Novavax against the recently emerged Middle East Respiratory Syndrome Coronavirus blocked infection in laboratory studies. UM SOM and Novavax also reported that a vaccine candidate against Severe Acute Respiratory Syndrome Coronavirus developed by Novavax on a similar platform also inhibited virus infection. This peer-reviewed manuscript describes a novel method to rapidly develop vaccines against previously unknown viruses, such as MERS-CoV, which appear suddenly and cause severe illnesses in humans.
News For NVAX From The Last 14 Days
Check below for free stories on NVAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 23, 2014
12:33 EDTNVAXNovavax strong data validates purchase of Isconova, says Ladenburg
Subscribe for More Information
08:47 EDTNVAXNovavax announces BARDA exercise of contract option
Subscribe for More Information
08:41 EDTNVAXNovavax H7N9 vaccine candidate delivers positive Phase 1/2 clinical data
Novavax announced positive top-line data from a Phase 1/2 clinical trial of its H7N9 Avian Influenza VLP Vaccine Candidate, or H7N9 VLP, with proprietary adjuvant Matrix-M. This trial was conducted under the company's contract with HHS-BARDA for the development of VLPs to address influenza strains with pandemic potential. The H7N9 VLP, with and without Matrix-M, was well tolerated and demonstrated a safety profile similar to the company's prior experience with another saponin-based adjuvant. Matrix-M adjuvanted formulations demonstrated a clear immunogenicity benefit relative to unadjuvanted antigen, and a dose-response within the adjuvanted groups. Antigen dose-sparing was shown, such that even the 3.75g dose of antigen with either tested dose of adjuvant gave immune responses statistically significantly greater than 15g dose without adjuvant. Geometric mean titers of hemagglutination-inhibiting antibody after two vaccine doses were comparable to those reported in prior studies with another saponin adjuvant when similar antigen and adjuvant doses were compared. The vaccine also elicited anti-neuraminidase antibodies against N9, with 89 to 100% sero-response rates in the adjuvanted vaccine groups, and greater than 11-fold increases in geometric mean titers.
September 19, 2014
07:41 EDTNVAXNovavax coverage assumed with an Outperform at Wedbush
Subscribe for More Information
September 18, 2014
11:16 EDTNVAXNovavax to host analyst and investor day
Subscribe for More Information
September 16, 2014
16:09 EDTNVAXNovavax initiates Phase 2 trial of RSV F vaccine candidate
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use